ライフサイエンスコーパス: nonviral

1 r gene therapy, whether using viral (53%) or nonviral (47%) vectors, have thus far disclosed no evide

2 generality of this approach, we engineered a nonviral, 60-subunit capsid, lumazine synthase from Aqui

3 ays, Th1 cytokine secretion, and by adding a nonviral Ag highly overexpressed in HPV-induced cancers.

4 r gene was 5-10 times higher than the common nonviral agents Fugene-6 and Lipofectamine in the presen

5 of specific cell-surface receptors for both nonviral and viral gene delivery vectors.

6 on either in naive mice or in the context of nonviral and viral immunogens.

7 zes cell membranes and offers a nonchemical, nonviral, and noninvasive method for cellular drug deliv

8 s report, we harnessed the highly efficient, nonviral, and plasmid-based piggyBac transposon system t

9 findings suggest a new paradigm of targeting nonviral antigens in immunotherapy of virally associated

10 In this paper, we show that nonviral apoptotic proteins can be displayed on viral me

11 ystemically in tumor-bearing mice by using a nonviral approach.

12 ct has clear advantages over viral and other nonviral approaches currently being tested.

13 plementing/replenishing miRNAs in vivo using nonviral approaches to boost protective immunity against

14 integration, as well as other site-selective nonviral approaches.

15 ) are up-regulated in PEL and other types of nonviral B-NHL.

16 nsidering that most RNA viruses tolerate few nonviral bases beyond their natural termini.

17 erminal bases, in the presence or absence of nonviral bases, generated progeny with a mixture of wt a

18 Nonviral, biodegradable polymeric nanoparticles were dev

19 ects the host against development of primary nonviral cancers but also sculpts tumor immunogenicity.

20 gy has been less successful in patients with nonviral cancers owing to their many and varied immune e

21 n engineered variant of lumazine synthase, a nonviral capsid protein with a negatively charged lumina

22 The DNAzyme in complex with a nonviral carrier also significantly inhibited tumor grow

23 er disease due to viral causes (HBV, HCV) or nonviral causes (alcohol-induced liver disease, autoimmu

24 hepatitis C virus infection (HCV), although nonviral causes also play a role in a minority of cases.

25 y HCV, but not against damage due to various nonviral causes.

26 at are compatible with all current viral and nonviral cell delivery methods.

27 e-associated TCRs could be identified in the nonviral chronic liver diseases primary biliary cirrhosi

28 used worldwide as gene vectors (carriers) in nonviral clinical applications of gene delivery, albeit

29 the main cause of cervical cancer, yet other nonviral cofactors are also required for the disease.

30 tent patients and in patients with viral and nonviral coinfections.

31 reover, this pathway also degrades AGO1 in a nonviral context, especially when the production of miRN

32 A promising nonviral delivery method for genetic vaccines involves m

33 Here we show that nonviral delivery of a 9-kb self-amplifying RNA encapsul

34 Alternative emerging strategies for nonviral delivery of CRISPR/Cas9 core components into hu

35 Efficient nonviral delivery of plasmid DNA to rat RPE in vivo was

36 Using a hydrodynamic-based, nonviral delivery protocol, we induced HCV transgene exp

37 ach has important implications for viral and nonviral delivery strategies for vaccines or gene therap

38 nst the EWS-FLI1 gene product by a targeted, nonviral delivery system dramatically inhibits tumor gro

39 The nonviral delivery system uses a cyclodextrin-containing

40 to mammalian cells and may serve as a potent nonviral delivery system.

41 nthetic, self-amplifying mRNA delivered by a nonviral delivery system.

42 Both viral vectors and nonviral delivery systems can be developed to circumvent

43 fects; and 382 articles describing viral and nonviral delivery systems.

44 liposome (CL)-DNA complexes are a prevalent nonviral delivery vector, but their efficiency requires

45 Our data suggest several viral and nonviral determinants of cervical HPV acquisition and cl

46 Viral and nonviral determinants of HPV acquisition and clearance w

47 unosuppression, the suspected role of MV in "nonviral" diseases such as multiple sclerosis and Paget'

48 cytes can be genetically programmed by using nonviral DNA and turned into powerful antigen-presenting

49 Nonviral DNA complexes are typically formed by combining

50 Nonviral DNA complexes show promise as alternative and a

51 nsfection and level of gene expression after nonviral DNA delivery remain low, suggesting the existen

52 Sleeping Beauty (SB) transposon system is a nonviral DNA delivery system in which a transposase dire

53 oratories are involved in the development of nonviral DNA delivery vehicles.

54 , we studied whether local gene therapy with nonviral DNA encoding VEGF and/or Ang1 into the ulcer ba

55 cellular transport of hundreds of individual nonviral DNA nanocarriers with 5-nm and 33-ms resolution

56 Nonviral DNA nanoparticles (NPs) can accommodate large g

57 eneimine (PEI) has been used previously as a nonviral DNA transfer vector.

58 A novel method for nonviral DNA transfer, called electron avalanche transfe

59 poly(beta-amino esters) for potential use as nonviral DNA vectors.

60 s in five assays that monitor insertion into nonviral DNA.

61 nanoparticles represent a new and promising nonviral DNA/gene delivery approach endowing immunomodul

62 eract prior viral immunity by priming with a nonviral, DNA vaccine.

63 Nonviral, DNA-mediated gene transfer is an alternative t

64 nct evolutionary origins, in particular from nonviral elements, and insufficient sampling to the spar

65 ct groups of archaeal viruses from different nonviral elements, providing important insights into the

66 budding of CD63 and several other viral and nonviral EMV proteins.

67 In sharp contrast, in nonviral, episomal plasmid DNA-injected mice, transgene

68 ntly larger than that for ESLD patients with nonviral etiologies.

69 with therapeutics for cancers with viral or nonviral etiologies.

70 e findings imply the potential importance of nonviral factors in natural SIV host species, such as in

71 brain barrier after i.v. administration of a nonviral formulation of the gene.

72 ected cells with biotinylated DNA encoding a nonviral gene and then infected the cells with wild-type

73 ute the common belief that the efficiency of nonviral gene carriers is dramatically reduced because o

74 ries of pyridinium cationic lipids useful as nonviral gene delivery agents were prepared by reaction

75 th viral gene transfer vectors and transient nonviral gene delivery approaches that are prevalent in

76 Oral nonviral gene delivery is the most attractive and arguab

77 ne approach using ORMOSIL nanoparticles as a nonviral gene delivery platform have a promising future

78 approach for breast cancer, consisting of a nonviral gene delivery system (SN) and a proapoptotic ge

79 es transgene expression in polycation-based, nonviral gene delivery systems, a number of CQ analogues

80 n of all systemically delivered nanoparticle nonviral gene delivery systems.

81 Nonviral gene delivery to the liver has been under evolu

82 ping Beauty (SB) transposon (Tn) system is a nonviral gene delivery tool that has widespread applicat

83 Quantitatively understanding how nonviral gene delivery vectors (polyplexes) are transpor

84 particles are ideal for use as a part of new nonviral gene delivery vectors.

85 These studies might help to develop novel nonviral gene delivery vehicles.

86 o nondividing cells, is a limiting factor in nonviral gene delivery.

87 important in vivo and for the improvement of nonviral gene delivery.

88 enhanced by anti-FasL mAb, suggesting that a nonviral gene product could be used to regulate the beha

89 This nonviral gene therapeutic approach led to persistent and

90 support further clinical development of this nonviral gene therapy approach.

91 NA (CL-DNA) complexes are abundantly used in nonviral gene therapy clinical applications.

92 This study demonstrates that a nonviral gene therapy combining the immunological proper

93 sease reversal and makes application of this nonviral gene therapy in humans with lupus (and perhaps

94 ategies for BTICs and establishes a flexible nonviral gene therapy platform with the capacity to chan

95 Nonviral gene therapy represents a promising treatment f

96 the use of small interfering RNA, viral and nonviral gene therapy, and microparticle or viscous gel

97 (bPEI) representing the current standard in nonviral gene therapy.

98 els of glioma, a lethal brain tumor, because nonviral gene transfer is typically transient.

99 Electroporation is one of the most popular nonviral gene transfer methods for embryonic stem cell t

100 the last major barrier to a fully successful nonviral gene transfer system for the liver.

101 Sleeping Beauty (SB) transposon is a natural nonviral gene transfer system that can mediate long-term

102 lls with Sleeping Beauty transposon-mediated nonviral gene transfer, highlighting the potential of th

103 Belagenpumatucel-L is a nonviral gene-based allogeneic tumor cell vaccine that d

104 uman IDO-encoding Sleeping Beauty (SB)-based nonviral gene-integrating approach, halted and attenuate

105 ed in FVIII-knockout (FVIII-KO) mice using a nonviral gene-transfer system.

106 was delivered to donor lungs in vivo using a nonviral gene-transfer vector, polyethylenimine.

107 e findings establish a practical approach to nonviral genetic correction of severe human genetic diso

108 the usefulness of electroporation-enhanced, nonviral genetic immunization for the active immunothera

109 a self-antigens, we used a novel strategy of nonviral genetic vaccination coupled with muscle electro

110 Current nonviral genetic vaccine systems are less effective than

111 FH and in 3 of 22 livers from patients with nonviral hepatic disease.

112 m individuals with viral (HCV and/or HBV) or nonviral hepatitis contained TCRgammadelta(+) T cells th

113 iopsy tissues obtained from individuals with nonviral hepatitis or from normal controls had no prefer

114 atients that is absent in liver tissues from nonviral hepatitis or healthy subjects.

115 ssociation between coffee intake and risk of nonviral hepatitis-related cirrhosis mortality (P for tr

116 rse relationship between caffeine intake and nonviral hepatitis-related cirrhosis mortality became nu

117 onstrates the protective effect of coffee on nonviral hepatitis-related cirrhosis mortality, and prov

118 The 5' ends of the mRNAs contain nonviral heterologous oligonucleotides that originate fr

119 ity achieved by using a lung-tissue-targeted nonviral human IDO gene transfer approach reduced, but d

120 to compare GP73 protein levels in viral and nonviral human liver disease and in normal livers, to id

121 nder cell-free conditions, which supported a nonviral hypothesis for the agent.

122 he strategy of combination of cisplatin with nonviral IL-2 gene therapy resulted in significant antit

123 ant immunity, we discuss analogous viral and nonviral immune concepts and propose working definitions

124 unnoticed in the realm of RNA silencing and nonviral immune responses.

125 tory functions in host immunity to viral and nonviral infections; however, the role of endogenous typ

126 ival was profoundly reduced during different nonviral inflammatory situations in the mouse, through a

127 Our results indicate that expression of a nonviral ITAM-containing protein is sufficient for cell

128 culture media in the laboratory diagnosis of nonviral keratitis.

129 lock TLR2-driven responses to both viral and nonviral ligands at or downstream of the MyD88 adaptor a

130 from patients with chronic HCV infection or nonviral liver disease to analyze markers of Tfh cells.

131 th spontaneous HCV resolution, patients with nonviral liver disease, and normal controls.

132 tients with hepatitis B and C and those with nonviral liver disease.

133 grase may be a simple and effective tool for nonviral long-term gene transfer in the eye.

134 of intron-containing HIV-1 gag RNA and also nonviral luc RNA.

135 /neck cancers, but the mechanisms underlying nonviral malignancies are unclear.

136 Taken together, our findings imply that nonviral maternal factors, such as the cytokine milieu,

137 Thus, SB provides a nonviral means for sustained FVIII gene delivery in a mo

138 The demonstration of a nonviral-mediated delivery of functional proteins into t

139 enesis, which are associated with viral- and nonviral-mediated gene therapy.

140 moderately hydrophobic segments of viral and nonviral membrane fusion proteins that enable these prot

141 cruitment, since it could be replaced with a nonviral membrane-binding domain without blocking active

142 ted lipofection is a comparatively efficient nonviral method for delivering genes to the corneal endo

143 The Sleeping Beauty (SB) transposon is a nonviral method of gene delivery that overcomes some of

144 A nonviral method of gene delivery was applied to transfec

145 DNA transposons offer an efficient nonviral method of permanently modifying the genomes of

146 om multiple inherited disease patients via a nonviral method.

147 The development of nonviral methods for efficient gene transfer to the lung

148 basis for developing safer, more efficient, nonviral methods for reprogramming human somatic cells.

149 More recently, various nonviral methods that avoid permanent and random transge

150 ansduction has been increasingly replaced by nonviral methods to generate induced pluripotent stem ce

151 iPSC derivation by transfection of a simple, nonviral minicircle DNA construct into human adipose str

152 ry of cardiac progenitor cells (CPCs) with a nonviral minicircle plasmid carrying HIF1 (MC-HIF1) into

153 soenzyme 2 and FIH were inserted into novel, nonviral, minicircle vectors.

154 advances in the mechanisms and strategies of nonviral miRNA delivery systems and provide a perspectiv

155 nistic rationale for the clinical testing of nonviral miRNA mimetics.

156 is report, we demonstrate systemic, in vivo, nonviral mRNA delivery through lipid nanoparticles (LNPs

157 genome into the 3' untranslated region of a nonviral mRNA leads to the specific encapsidation of thi

158 ough N can augment translation initiation of nonviral mRNA, initiation of viral mRNA by N is superior

159 iral RNAs and with our study of encapsidated nonviral mRNAs containing inserts of viral sequence.

160 efficiency; therefore it may become a novel nonviral nanosystem for gene delivery.

161 This nonviral, non-stem cell approach enables autologous, adu

162 However, telomere extension by nonviral, nonintegrating methods remains inefficient.

163 RNA.VEGF-A-loaded PLGA NPs are an effective, nonviral, nontoxic, and sustainable form of gene therapy

164 linical implementation of safe and effective nonviral nucleic acid therapeutics, and preparation with

165 e augmented by other means in vivo to render nonviral oral gene delivery practical.

166 Single-stranded RNA (ssRNA) molecules of nonviral origin also induce TLR7-dependent production of

167 lymphomas and HCCs, but not in lymphomas of nonviral origin or HBV-associated HCC.

168 as well as an additional 66 bp insertion of nonviral origin.

169 edge, the first known human -1 PRF signal of nonviral origin.

170 ponses to these LCMV CD4 epitopes as well as nonviral, OVA-specific responses were actively suppresse

171 n be detrimental to the host in a variety of nonviral pathogen infection models.

172 est Nile virus), and 3 had coinfections with nonviral pathogens (2 with Ehrlichia chaffeensis and 1 w

173 nd 2 with varicella zoster virus) and 3 with nonviral pathogens (2 with pneumococcus and 1 with Crypt

174 by which MPYS mediates host defense against nonviral pathogens are unknown.

175 and demethylation in plant immunity against nonviral pathogens.

176 peripheral blood and was transfected using a nonviral plasmid carrying complementary DNA for modified

177 mphocytes can be genetically programmed with nonviral plasmid DNA for the biogenesis and delivery of

178 noninvasive intravenous administration of a nonviral plasmid formulation.

179 ing Beauty (SB) transposon is an integrative nonviral plasmid system.

180 noninvasive intravenous administration of a nonviral plasmid that is reformulated with gene-targetin

181 the site around the ulcer was injected with nonviral plasmid-encoding full-length complementary DNA

182 ene delivery and increased the efficiency of nonviral platforms to levels previously attained only by

183 tuation is perhaps most prevalent in current nonviral polycationic gene-delivery systems in which the

184 l of nature's most efficient DNA viruses and nonviral polyethylenimine/DNA nanocomplexes were reveale

185 cells are often difficult to transfect using nonviral polyplexes.

186 In nonviral preclinical models, the angiogenic cytokine VEG

187 Nonviral producer cell proteins incorporated into retrov

188 that elements of the latency locus protect a nonviral promoter against silencing in primary human cel

189 e cells, including HSCs, and accommodating a nonviral promoter to control the transgene expression in

190 Bacterial encapsulins are a class of nonviral protein cages that self-assemble in vivo into s

191 positive selection in a variety of viral and nonviral protein-coding genes.

192 expedient means for generating novel mutant nonviral proteins in mammalian cells.

193 Remarkably, nonviral proteins made up about two thirds of VC protein

194 d approach can be applied to other viral and nonviral proteins.

195 nsignificant pathology, acute rejection, and nonviral pulmonary infection.

196 proteins between Z and Xenopus Neuralized, a nonviral RING finger protein, indicated that the structu

197 Nonviral risk factors for acquisition of HR HPV infectio

198 Efficient incorporation into BMV virions of nonviral RNA chimeras containing NE and the PE provides

199 er is able to discriminate between viral and nonviral RNA molecules and, interestingly, recognizes an

200 plex that can discriminate between viral and nonviral RNA molecules during the early steps of the enc

201 capable of altering the binding potential of nonviral RNA to levels seen with wild-type vRNAs.

202 o minimize the risk of accidental capping of nonviral RNA when Pol is dormant.

203 s 3' deletion mutants of both vRNA and cRNA, nonviral RNA, and hybrid viral/nonviral RNA, were analyz

204 This region, if placed within nonviral RNA, is capable of altering the binding potenti

205 prevents HBV core protein from assembling on nonviral RNA, preserving the protein for virus productio

206 RNA and cRNA, nonviral RNA, and hybrid viral/nonviral RNA, were analyzed for their ability to interac

207 confer 1a-induced membrane association on a nonviral RNA.

208 bility to transform the binding potential of nonviral RNA?

209 st that APOBEC3G interactions with viral and nonviral RNAs that are packaged into viral particles are

210 RNA replication signals, which also directed nonviral RNAs to P bodies.

211 Equivalently sized nonviral RNAs, including high copy potential in vivo com

212 e S-IGR of Lassa virus (LASV) or an entirely nonviral S-IGR-like sequence (Ssyn), are viable, indicat

213 The maintenance of such a nonviral sequence was surprising considering that most R

214 than specific sequences, we examined whether nonviral sequences can be used to facilitate minus-stran

215 These data indicated that nonviral sequences could be used to efficiently mediate

216 were constructed to contain substitutions of nonviral sequences in place of bases 21 to 72 of the ant

217 We further report that nonviral sequences that are rapidly deleted from recombi

218 t of the ACMV origin of replication flanking nonviral sequences that can be mobilized and replicated

219 e proteins more efficiently than did control nonviral sequences, suggesting that it might be involved

220 es of viral ssRNAs are smaller than those of nonviral sequences.

221 onas vaginalis, which causes the most common nonviral sexually transmitted disease worldwide, is itse

222 and causes trichomonosis, the most prevalent nonviral sexually transmitted disease.

223 chomonas vaginalis is one of the most common nonviral sexually transmitted human infections and, worl

224 richomonas vaginalis (TV) is the most common nonviral sexually transmitted infection (STI) in the wor

225 Trichomoniasis vaginalis is the most common nonviral sexually transmitted infection (STI) worldwide,

226 is estimated to be the most widely prevalent nonviral sexually transmitted infection in the world.

227 Trichomonas vaginalis is the most prevalent nonviral sexually transmitted infection worldwide, and i

228 chomonas vaginalis causes the most prevalent nonviral sexually transmitted infection worldwide.

229 ponsible for trichomoniasis, the most common nonviral sexually transmitted infection worldwide.

230 Trichomonas vaginalis is the most prevalent nonviral sexually transmitted infection, affecting an es

231 Trichomoniasis vaginalis, the most prevalent nonviral sexually transmitted infection, is associated w

232 euraminidase repeats that are a signature of nonviral sialidases.

233 , this is the most efficacious and selective nonviral siRNA delivery system for gene silencing in hep

234 or the safety and efficacy of this targeted, nonviral siRNA delivery system.

235 pplicable therapeutic strategy that involves nonviral siRNA delivery to ameliorate the response to va

236 cells (ECs) in vitro and use a rapid 10-min nonviral siRNA transfection technique to determine the e

237 s that biological pressures on the choice of nonviral sites would be minimal was validated when most

238 We tested the safety of a nonviral somatic-cell gene-therapy system in patients wi

239 sequence with higher affinity than to other nonviral ssRNA sequences.

240 , we predict the average MLD values of large nonviral ssRNAs scale as N(0.67+/-0.01), where N is the

241 ings indicate that replacement of L-IGR by a nonviral Ssyn could serve as a universal molecular deter

242 One of these is the first identified nonviral substrate for Nedd4-mediated monoubiquitylation

243 These nonviral synthetic IGRs can be used as universal molecul

244 us to generate recombinant LCMVs containing nonviral synthetic IGRs.

245 afe DNA delivery that has great promise as a nonviral system of gene transfer.

246 on, and retroviral integration, we propose a nonviral system that would potentially allow for site-se

247 We have therefore investigated the use of a nonviral system, transferrin-mediated lipofection, to tr

248 of this protein residue in the selection of nonviral target DNA sites is likely to be a general prop

249 rus type 1 integrase, affected the choice of nonviral target DNA sites.

250 integrases for alterations in the choice of nonviral target DNA sites.

251 s suggest that a comprehensive evaluation of nonviral technologies to deliver self-amplifying RNA vac

252 ds great promise for human gene therapy as a nonviral technology to deliver therapeutic genes.

253 llowing RNA transfection is due, in part, to nonviral terminal sequences present in the in vitro-deri

254 We found that a 2-part nonviral Tet-KRAB inducible expression system repressed

255 V entry and replication and can be important nonviral therapeutic targets.

256 ctors is a major concern when novel viral or nonviral therapeutics are proposed for applications in h

257 For this reason, they are promising nonviral transfection agents.

258 lated with those needed to achieve efficient nonviral transfection in vivo.

259 Although various nonviral transfection methods are available, cell toxici

260 t retinal pigment epithelium (RPE), by using nonviral transfection methods for gene transfer and the

261 Current nonviral transfection methods, empirically designed to m

262 ion of gene expression in central neurons by nonviral transfection techniques, including production o

263 ity of viral vectors and the inefficiency of nonviral transfection techniques.

264 e large research effort focused on enhancing nonviral transfection vectors has clearly demonstrated t

265 t this hypothesis, we have generated using a nonviral transformation procedure a bone marrow-derived

266 Both viral and nonviral tumor antigen-specific T cells resided predomin

267 r directed to the diasialoganglioside GD2, a nonviral tumor-associated antigen expressed by human neu

268 T cells specific for LMP as well as nonviral tumor-associated antigens (epitope spreading) c

269 Cytotoxic T lymphocytes (CTLs) directed to nonviral tumor-associated antigens do not survive long t

270 th most viral vectors, we believe this novel nonviral vector can be of great value for cardiac gene t

271 The SB-Tn system is a promising nonviral vector for efficient genomic insertion conferri

272 modified silica (ORMOSIL) nanoparticles as a nonviral vector for efficient in vivo gene delivery.

273 ganically modified silica nanoparticles as a nonviral vector for gene delivery and biophotonics metho

274 A nonviral vector for highly efficient site-specific integ

275 ansposon (SB-Tn) has emerged as an important nonviral vector for integrating transgenes into mammalia

276 Both viral and nonviral vector gene delivery systems have been used to

277 The improved understanding of what limits nonviral vector gene transfer efficiency in vivo has res

278 To our knowledge, no nonviral vector has been proposed that allows for the po

279 was soon recognized that the properties of a nonviral vector resulting in efficient transfection in v

280 is study, we investigated the use of a novel nonviral vector system, the Sleeping Beauty (SB) transpo

281 In this study, we develop a novel nonviral vector that robustly and persistently expresses

282 possible after the i.v. administration of a nonviral vector with the combined use of gene targeting

283 We designed a nonviral vector, PEI-PEG-DUPA (PPD), comprising polyethy

284 prove the efficiency of gene transfer by the nonviral vector.

285 concerns regarding their use in humans make nonviral vectors an attractive alternative.

286 on skipping, to gene therapy using viral and nonviral vectors and cell-based approaches.

287 subtle changes in the physical properties of nonviral vectors and provides a basis for the definition

288 Consequently, nonviral vectors can incorporate numerous vector composi

289 demonstrations established relatively simple nonviral vectors could mediate gene expression in HepG2

290 new understandings in the rational design of nonviral vectors for efficient gene delivery.

291 Such systems have high potential as nonviral vectors for gene delivery and will allow for mo

292 biochemical mechanisms associated with using nonviral vectors for gene delivery.

293 Research into the design of suitable nonviral vectors has been slow.

294 Gene therapy based on delivery of viral and nonviral vectors has shown great promise for the treatme

295 e advantages, gene-delivery strategies using nonviral vectors have poorly translated into clinical su

296 Nonviral vectors, on the other hand, offer safety but ha

297 Among the nonviral vectors, the lipoplexes (complexes of cationic

298 molecules, utilizing a variety of viral and nonviral vectors, to induce antigen-specific immune resp

299 delivery are usually classified as viral and nonviral vectors.

300 This article reviews both viral and nonviral work with focus on two candidates for clinical